A phase 1 study (NCT01765790) assessed the safety, pharmacokinetics, tolerability, and antitumor activity of a humanized anti-MIF monoclonal antibody (Imalumab) against solid cancers consisting primarily of colorectal carcinoma (50%), ovarian carcinoma (20%), and non-small cell lung carcinoma (NSCLC—14%) (196). Here, MIF is linked to ovarian carcinoma.